COVID-19
PRODUCT SEARCH
REPORTING OF SIDE EFFECTS TO MEDICINES OR VACCINES
NPRA mission
NPRA mission is to safeguard the nation’s health through scientific excellence in the regulatory control of medicinal products and cosmetics.
New Route under the Facilitated Registration Pathway (FRP): A One-Year Pilot Study Commencing 2 May 2026 |
Mesalazine: Risk of Idiopathic Intracranial Hypertension (IIH) |
Moxifloxacin: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), Fixed-Drug Eruption (FDE), and Photosensitivity Associated with Systemic Use |
Directives & Circulars (GCP & GLP) |
Sunitinib: Risk of Hyperammonaemic Encephalopathy |
| 04 Sep 2025; 08:00AM - 05:00PM Bengkel Pengujian Kawalan Kualiti Bahan Mentah Herba Bagi Produk Semulajadi |





































